CTOs on the Move

Neomorph

www.neomorph.com

 
Neomorph is a venture backed biotechnology company based in San Diego, California.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Neomorph raised $109M on 12/22/2020

Similar Companies

Panomics

Panomics is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AC Immune

AC Immune SA, a global leader in developing precision medicine for neurodegenerative diseases (incl. Alzheimer & Parkinsons) with cutting-edge technology platforms

Pneuma Respiratory

Founded in 2015, Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD. Pneuma is leveraging more than three decades of healthcare research and product development experience along with hand held device design and manufacturing expertise.

New Economy Strategies

New Economy Strategies is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inovio

Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer and 69% of vulvar cancer. In addition to HPV, Inovio`s optimized plasmid design and delivery technology have been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio`s most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, GBM, and prostate cancer, as well as externally funded vaccine development programs in Zika, MERS, Lassa, HIV, and COVID-19. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. Inovio also is a proud recipient of 2020 Women on Boards “W” designation recognizing companies with more than 20% women on their board of directors.